Home
Novimmune SA

Novimmune SA Market Share Analysis for July 2026

28 August 2019 Hits: 1290776

Health > Biotechnology and Pharmaceuticals

Domainnovimmune.com

Year Founded1998

Employees51 - 200

Annual Revenue$25M - $50M

Novimmune SA

Novimmune SA (including company regionals)

novimmune.com

See more website traffic and engagement information

Novimmune SA Revenue up to July 2026 is 25M - 50M

revenue generated by Novimmune SA top domains

Novimmune SA top domains revenue over 3 years

Revenue for Novimmune SA top domains

novimmune.com25M - 50M

See more with Sales Intelligence

Total visits to Novimmune SA's top domains

Understand Novimmune SA market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Novimmune SA's top domains

Analyze Novimmune SA engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Novimmune SA's top domains

See how Novimmune SA keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Novimmune SA top competitors by domain

Top similar sites in July 2026, ranked by their affinity

acimmune.comCompany NameAC ImmuneEmployees51 - 200HQSwitzerland, LausanneAnnual revenue$2M - $5MTotal visits6.6KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Novimmune SA

These are the website technologies, by industry, used by Novimmune SA top domains

Payment & Currencies (22)

PayPal

Conversion & Analytics (3)

Google Analytics

Mobile (2)

Meta Viewport

Widget (2)

reCAPTCHA

More Technologies

2

See all

News & Signals from Novimmune SA

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsNovimmune SA is developing monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10.It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.

NewsNovimmune SA is developing products containing toll-like receptor 4 and chemokine ligand 10.It has a collaboration agreement with NovImmune SA to develop products containing toll-like receptor 4 and chemokine ligand 10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions.